1300735-17-4

Upstream product

• 5399-03-1 2-iodo-1-methoxy-4-nitrobenzene 
• 1300737-57-8 Ethyl 4-{[2-(1,1-di methylethyl)phenyl]amino}-7-(3,5-dimethyl-4-isoxazolyl)-6-(methoxy)-3-quinolinecarboxylate 
• 1300737-56-7 ethyl 4-chloro-7-(3,5-dimethyl-4-isoxazolyl)-6-(methoxy)-3-quinolinecarboxylate 
• 1300031-59-7 C₁₈H₁₈N₂O₅ 
• 1300031-60-0 1,3-diethyl 2-([[3-(3,5-dimethyl-1,2-oxazol-4-yl)-4-methoxyphenyl]amino]methylidene)propanedioate 
• 1300031-61-1 [3-(3,5-dimethyl-4-isoxazolyl)-4-(methyloxy)phenyl]amine 
• 1300031-62-2 3,5-dimethyl-4-[2-(methyloxy)-5-nitrophenyl]isoxazole 
• 1300859-10-2 C₂₆H₂₇N₃O₄ 
• 16114-47-9 3,5-dimethylisoxazole-4-boronic acid 

Relevant academic research and scientific papers

Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors

Novel compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.

From ApoA1 upregulation to BET family bromodomain inhibition: Discovery of I-BET151

The discovery, synthesis and biological evaluation of a novel series of 7-isoxazoloquinolines is described. Several analogs are shown to increase ApoA1 expression within the nanomolar range in the human hepatic cell line HepG2.

IMIDAZO [4, 5-C] QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS

Novel compounds of Formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.